ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on May 12, 2017, covering events occurring on May 8, 2017, and May 12, 2017. The filing details corporate actions taken in connection with the Company's initial public offering (IPO) of units, which closed on May 12, 2017. The Company is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data provided relates to executive compensation and the IPO pricing:
- Offering Price: $5.00 per unit.
- CEO Base Salary (Francois Michelon): $325,000 annually.
- CTO Base Salary (Michael Thornton): $245,000 annually.
- CFO Consulting Fee (David Wells via StoryCorp): $9,000 monthly.
Material Changes
The filing reports two significant material changes to the Company's capital structure and governance:
- Reverse Stock Split: On May 8, 2017, the Company effected a one-for-3.5 reverse split of its Common Stock. This became effective at 11:59 p.m. Eastern Time on that date. There was no reduction in authorized capital stock.
- Executive Compensation Agreements: New employment and consulting agreements were executed effective May 12, 2017, coinciding with the IPO closing.
Guidance, Outlook, and Management Commentary
The filing does not provide forward-looking guidance, revenue outlook, or management commentary on market conditions. It focuses strictly on the execution of the IPO-related agreements and the reverse split. Key terms of the new agreements include:
- Stock Options for CEO and CTO: Options granted to purchase shares such that, combined with existing holdings, each officer holds 5.0% of the Company's total issued and outstanding shares on a fully diluted basis. The exercise price is $5.00, vesting in three equal annual installments.
- Stock Options for CFO: An option to purchase 15,000 shares at $5.00 per share, vesting in twelve equal quarterly installments. An identical option is to be granted annually.
- Charter Amendment: The Company filed a Fourth Amended and Restated Certificate of Incorporation on May 9, 2017.
Investor Verification Checklist
- Verify the impact of the one-for-3.5 reverse split on existing shareholdings and trading volume.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for complete details on executive compensation, vesting schedules, and termination provisions.
- Confirm the total number of shares outstanding post-split and post-IPO to validate the 5.0% ownership calculation for the CEO and CTO.
- Check the Prospectus filed on May 10, 2017, for comprehensive risk factors and use of proceeds from the $5.00 per unit offering.